ESC Premium Access

Usefulness of fibroblast growth factor 23 and soluble suppression of tumorigenicity 2 as predictors of poor outcome in heart failure with preserved ejection fraction

Congress Presentation

About the speaker

Doctor Clotilde Roy

Jolimont Lobbes Hospital, La Louviere (Belgium)
1 presentation
0 follower

9 more presentations in this session

Prognostic impacts of soluble form of basigin in patients with chronic heart failure -from a prospective large clinical trial with 1,147 patients-

Speaker: Associate Professor K. Satoh (Sendai, JP)


Mid regional atrial natriuretic peptide is an independent predictor of peak pulmonary capillary wedge pressure in patients with heart failure with preserved ejection fraction

Speaker: Doctor S. Nanayakkara (Melbourne, AU)


Association of NGAL and AHEAD score for two-year prognosis in chronic heart failure patients (FAR NHL registry)

Speaker: Doctor K. Labr (Brno, CZ)


Machine learning facilitates selecting a group of metabolites non-inferior to BNP for the diagnosis of chronic heart failure

Speaker: Doctor M. Marcinkiewicz-Siemion (Bialystok, PL)


Optimizing patient selection in heart failure trials: the role of NT-proBNP

Speaker: Doctor G. Savarese (Stockholm, SE)


Access the full session

Exploring biomarkers in heart failure

Speakers: Doctor C. Roy, Associate Professor K. Satoh, Doctor S. Nanayakkara, Doctor K. Labr, Doctor M. Marcinkiewicz-Siemion...

About the event


ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb